Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2024 August Clinical trials Recent developments in the treatment of acute myeloid leukaemia Read more
2023 March Clinical practice Anaemia as a mediator of adverse pregnancy outcomes in sickle cell disease Read more
Top
